Table 2.
Characteristics of participants from included studies.
| Study | N (size) | Arms | N (arms) | Male % | Mean age (SD) | Mean age at onset | Baseline CY-BOCS | Completed the study (%) | Responders* (%) | Remission** (%) |
|---|---|---|---|---|---|---|---|---|---|---|
| Alaghband-Rad and Hakimshooshtary (28) | 29 | Fluoxetine | 15 | 58.6 | 14 ± 2.4 | NR | 26.7 ± NR | 82.8 | NR | NR |
| Citalopram | 14 | 28.0 ± NR | NR | NR | ||||||
| Asbahr et al. (27) | 40 | SSRI | 20 | 65.0 | 13 ± 2.5 | 9 ± 3.2 | 27.0 ± 6.7 | 97.5 | 90.0 | NR |
| CBT | 20 | 26.3 ± 4.9 | 95.0 | NR | ||||||
| Geller et al. (30) | 103 | SSRI | 71 | 47.6 | 11 ± 2.9 | NR | 24.5 ± 5.1 | 67.0 | 49.3 | NR |
| Placebo | 32 | 26.3 ± 4.6 | 25.0 | NR | ||||||
| Geller et al. (31) | 203 | SSRI | 98 | 57.6 | 11 ± 3 | 8 ± 3.1 | 24.4 ± 5.0 | 71.4 | 62.2 | NR |
| Placebo | 105 | 25.3 ± 5.1 | 40.0 | NR | ||||||
| Liebowitz et al. (29) | 43 | SSRI | 21 | 58.1 | 13 ± 2.7 | NR | 22.5 ± 4.2 | 88.4 | 57.1 | NR |
| Placebo | 22 | 23.8 ± 5.8 | 31.8 | NR | ||||||
| March and Friesen (32) | 187 | SSRI | 92 | NR | 13 ± NR | 8 ± NR | 23.4 ± 4.6 | 83.4 | 53.3 | NR |
| Placebo | 95 | 22.2 ± 6.2 | 36.8 | NR | ||||||
| Neziroglu et al. (26) | 10 | SSRI + CBT | 5 | 60.0 | 15 ± 2.4 | 10 ± NR | 28.0 ± 5.6 | 100.0 | 40.0 / 80.0* | 0.0 |
| SSRI | 5 | 22.8 ± 3.8 | 0.0 / 20.0* | 0.0 | ||||||
| POTS (4) | 112 | CBT | 28 | 50.0 | 12 ± 2.7 | NR | 26.0 ± 4.7 | 86.6 | NR | 39.3 |
| SSRI | 28 | 23.5 ± 4.7 | NR | 21.4 | ||||||
| SSRI + CBT | 28 | 23.8 ± 3.0 | NR | 53.6 | ||||||
| Placebo | 28 | 25.2 ± 3.3 | NR | 3.6 | ||||||
| Riddle et al. (25)** | 14 | SSRI | 7 | 42.9 | 12 ± 2.3 | NR | 24.3 ± 4.2 | 92.9 | NR | NR |
| Placebo | 7 | 20.2 ± 7.7 | NR | NR | ||||||
| Riddle et al. (33) | 120 | SSRI | 57 | 53.3 | 13 ± NR | 9.4 ± NR | 24.2 ± 4.4 | 61.7 | 42.1 | NR |
| Placebo | 63 | 24.2 ± 4.8 | 27.0 | NR | ||||||
| Skarphedinsson et al. (18) | 50 | SSRI | 22 | 48.0 | 14 ± 2.7 | NR | 21.1 ± 3.7 | 72.0 | 45.5 / 45.5* | 27.3 |
| CBT | 28 | 21.3 ± 4.0 | 35.7 / 50.0* | 32.1 | ||||||
| Storch et al. (24) | 47 | reg SSRI + CBT | 14 | 61.7 | 14 ± 2.7 | NR | 23.6 ± 4.5 | 70.2 | 57.1 | 42.9 |
| slow SSRI + CBT | 17 | 26.7 ± 5.7 | 64.7 | 26.5 | ||||||
| Placebo + CBT | 16 | 25.1 ± 4.0 | 62.5 | 18.8 | ||||||
| TOTAL | 958 | 43.7 | 76.6 | 39.5 %*** | 6.4 |
NR, not reported.
Where missing in the articles, the data were either calculated from other reported values or, where appropriate, previous meta-analyses were consulted.
*Responders were defined differently across studies: 25% reduction of CY-BOCS from baseline (27, 31–33), 30% reduction from baseline (18, 24) 40% reduction from baseline (30), end-treatment CY-BOCS ≤ 16 (18), and not otherwise specified (29). Neziroglu et al. (26) did not specifically report response and remission rates, which were calculated from the raw data and 25 % or 30% reductions/CY-BOCS ≤16 are presented in the corresponding row. 30% reduction/CY-BOCS ≤16 are presented for the row of Skarphedinsson et al. (18).
**Remission was defined as CY-BOCS ≤11.
***Only 30% reduction rates were taken into account for Neziroglu et al. and Skarphedinsson et al.